Table 3.
Immunosuppression regimen (Reference: IL2rAb) |
No. of centers in pairwise comparison |
No. of centers significantly above reference probability |
No. of centers significantly below reference probability |
---|---|---|---|
Thymoglobulin | 253 | 105 (43.2%) | 116 (44.7%) |
Alemtuzumab | 123 | 51 (38.7%) | 52 (10.5%) |
Other | 132 | 40 (32.0%) | 38 (19.5%) |
No induction | 256 | 89 (35.7%) | 115 (43.2%) |
Constructed from pairwise comparisons of regimen of interest versus reference regimen (IL2rAb).
IL2rAb, interleukin-2 receptor blocking antibodies.